Alzheimer’s disease, frontotemporal dementias, progressive supranuclear palsy, Corticobasal degeneration,   Clinical Trial Study

A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome (ROCKIT-1 ROCK Inhibitor in Tauopathies-1)

ID
NCT04734379
Condition Studied
Corticobasal Degeneration
Progressive Supranuclear Palsy
Phase
Phase II
Status
Closed
Intervention
Fasudil

Please go to ClinicalTrials.gov for more information.